NCT03519178 2025-11-14
A Study of PF-06873600 in People With Cancer
Pfizer
Phase 1/2 Terminated
Clinical Trials
13 trialsNCT05261490 2024-11-19
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
Phase 1/2 Terminated
NCT05001282 2024-08-07
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
Phase 1/2 Terminated
NCT00889733 2024-03-26
OVHM-01
University Health Network, Toronto
Phase 1/2 Terminated
NCT01962948 2024-03-26
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT03330405 2023-10-13
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT03100006 2022-06-13
ORION-01
National Cancer Centre, Singapore
Phase 1/2 Terminated
NCT01334047 2021-02-26
Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients
Oslo University Hospital
Phase 1/2 Terminated
NCT02012192 2019-08-13
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
Medical University Innsbruck
Phase 1/2 Terminated
NCT00903630 2017-12-28
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 1/2 Terminated
NCT00005612 2012-09-26
ETC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00085384 2012-08-02
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00034138 2007-12-18
A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
Unither Pharmaceuticals
Phase 1/2 Terminated